Skip To Main Content
Chung-Han Lee on Muck Rack

Chung-Han Lee

As seen in: Nature, Wiley Online Library, Memory Studies, MDPI, JAMA Oncology, Royal Society of Chemistry, The Lancet, Cell Press, Healio, Molecular Cancer Research and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chung-Han

Contact Chung-Han, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multiple Imputation Confidence Intervals for a Risk Difference With Missing Observations

|
By Chung-Han Lee
| Wiley Online Library Verified
Conflicts of Interest The author declares no conflicts of interest. Supporting Information Filename Description sim70136-sup-0001-Data1.csvCSV document, 5.3 KB Data S1. Supporting Information. sim70136-sup-0002-Data2.txtplain text document, 6.1 KB Data S2. Supporting Information. sim70136-sup-0003-Supinfo.pdfPDF document, 2.6 MB Data S3. Supporting Information. References 1, , and , “Interval estimation in exponential families,” Statistica Sinica 13 (2003): 19–49.
Open in Who Shared Issue with article?

A Biomechanical Evaluation of Distal Tilting Implants in All-on-Four Rehabilitation with Mild Mandibular Resorption: A Finite Element Analysis Study

|
By Ming-Hsu Tsai, Chung-Han Lee, Aaron Wu, Yao-Ning Lei
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

|
By Kelly Fitzgerald, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Chung-Han Lee, Laura Peralta, Yingbei Chen, Robert A. Lefkowitz, Neil Shah Verified, Colette N. Owens, Deaglan J. McHugh, David H Aggen, Ritesh R. Kotecha, Andrew L. Laccetti, Darren R. Feld
| European Urology Verified
Abstract Treatment options are limited for patients with non–clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib plus nivolumab. We now report updated efficacy and safety results at median follow-up of 34 mo for patients with papillary, unclassified, or translocation-associated RCC.
Open in Who Shared Issue with article?
See all 34 licensed articles (44 Total)